Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive, Randomized, Double Blind, Placebo Controlled Three Part Study of the Safety, Tolerability, and Pharmacokinetics of MRX-8 Administered Intravenously to Healthy Volunteers in Single Ascending and Multiple Ascending Dose Cohorts

Next Previous
Trial Profile

An Adaptive, Randomized, Double Blind, Placebo Controlled Three Part Study of the Safety, Tolerability, and Pharmacokinetics of MRX-8 Administered Intravenously to Healthy Volunteers in Single Ascending and Multiple Ascending Dose Cohorts

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRX 8 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors MicuRx Pharmaceuticals

Most Recent Events

  • 23 Aug 2023 Status changed from recruiting to completed.
  • 16 Dec 2020 Status changed from not yet recruiting to recruiting.
  • 13 Aug 2020 According to a MicuRx Pharmaceuticals media release, FDA has completed review of the IND application and gave clearance for this trial to proceed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top